{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 408766144
| IUPAC_name = 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-<nowiki>[[</nowiki>(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
| image = Mupirocin structure.png
| width = 320
| alt = 무피로신의 주성분인 슈도몬산 A (PA-A)
| image2 = Mupirocin molecule ball.png
| alt2 = Ball-and-stick model of the pseudomonic acid A molecule, the principal component of mupirocin
| caption = Pseudomonic acid A (PA-A), the principal component of mupirocin

<!--Clinical data-->
| tradename = Bactroban, others
| synonyms = muciprocin<ref>{{서적 인용|last1=Fleischer|first1=Alan B.|title=Emergency Dermatology: A Rapid Treatment Guide|date=2002|publisher=McGraw Hill Professional|isbn=9780071379953|page=173|url=https://books.google.com/books?id=YEk-H5mcgYcC|language=en|url-status=live|archive-url=https://web.archive.org/web/20170910183359/https://books.google.com/books?id=YEk-H5mcgYcC&q|archive-date=2017-09-10}}</ref>
| Drugs.com = {{drugs.com|monograph|mupirocin}}
| MedlinePlus = a688004
| pregnancy_AU = B1
| pregnancy_category =
| legal_AU = S4
| legal_US = Rx
| legal_CA = OTC<ref>{{웹 인용 |title=Drug Product Database Online Query |url=https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do;jsessionid=81220636FC4B15D98A19DD166B40AF10 |website=health-products.canada.ca |access-date=30 July 2019 |language=en |archive-date=2019-07-30 |archive-url=https://web.archive.org/web/20190730151903/https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do;jsessionid%3D81220636FC4B15D98A19DD166B40AF10 |url-status= }}</ref>
| legal_UK = POM
| routes_of_administration = Topical
| licence_US = Bactroban

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 97%
| metabolism =
| elimination_half-life = 20 to 40 minutes

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 12650-69-0
| ATC_prefix = D06
| ATC_suffix = AX09
| ATC_supplemental = {{ATC|R01|AX06}}
| PubChem = 446596
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00410
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 393914
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = D0GX863OA5
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01076
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7025
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 719

<!--Chemical data-->
| C=26 | H=44 | O=9
| smiles = O=C(O)CCCCCCCCOC(=O)\C=C(/C)C[C@@H]2OC[C@H](C[C@@H]1O[C@H]1[C@@H](C)[C@@H](O)C)[C@@H](O)[C@H]2O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MINDHVHHQZYEEK-HBBNESRFSA-N
| melting_point = 77
| melting_high = 78
|drug_name=|type=|legal_status=|licence_EU=}}
<!-- Definition and medical uses -->
'''무피로신'''({{llang|en|mupirocin}})은 [[농가진]]이나 [[모낭염]]과 같은 표재성 [[피부 감염]]에 유용한 국소 [[항생제]]이다. 무피로신은 '''박트로반'''({{llang|en|Bactroban}})이라는 상품명으로 판매된다.<ref>{{저널 인용|last1=AlHoufie |first1=Sari Talal S. |last2=Foster |first2=Howard A. |title=Effects of sub-lethal concentrations of mupirocin on global transcription in Staphylococcus aureus 8325-4 and a model for the escape from inhibition |journal=Journal of Medical Microbiology |date=1 August 2016 |volume=65 |issue=8 |pages=858–866 |doi=10.1099/jmm.0.000270|pmid=27184545 |doi-access=free }}</ref><ref name=AHFS2016>{{웹 인용|title=Mupirocin|url=https://www.drugs.com/monograph/mupirocin.html|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161221005721/https://www.drugs.com/monograph/mupirocin.html|archive-date=21 December 2016}}</ref><ref name=WHO2008>{{서적 인용| title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | publisher = World Health Organization | page = 298 }}</ref> 무피로신은 또한 증상 없이 코에 존재할 때 [[메티실린 내성 황색포도상구균]](MRSA)을 제거하는 데 사용할 수 있다.<ref name=AHFS2016/> [[항생제 내성|내성]]이 생길 우려가 있으므로 10일 이상 사용하지 않는 것이 좋다.<ref name=WHO2008/> 무피로신은 피부에 바르는 크림이나 연고로 사용된다.<ref name=AHFS2016/>

== 같이 보기 ==
* [[항생제]]
* [[항생제 내성]]

== 각주 ==
{{각주}}

[[분류:항생물질]]
[[분류:카복실산 에스터]]
[[분류:에폭사이드]]
[[분류:지방산]]
[[분류:글락소스미스클라인의 제품]]
[[분류:세계 보건 기구 필수 의약품]]